2 results
Approved WMORecruiting
Primary(Part I and Part II):- To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) in the QW and/or Q3W regimens of RO7122290 in combination with cibisatamab after pretreatment with obinutuzumab- To characterize the…
Approved WMOPending
The major objective of this clinical investigation is to demonstrate safety and effectiveness of the ablation system (OMNYPULSE* Bi-Directional Catheter and TRUPULSE* Generator) when used for isolation of the atrial PVs in treatment of subjects with…